



ADULT Medication Monograph

CARBOPROST

This document should be read in conjunction with this [DISCLAIMER](#)



⚠ HIGH RISK

Do not use in women with cardiac or pulmonary disease, hepatic or renal insufficiency, or allergy to prostaglandins. Use with caution in women with asthma

SAS Category A (item requires approval by TGA)

Presentation	Ampoule: 250microg/mL (SAS) <i>Also known as 15-methyl prostaglandin F2α</i>
Dose	<u>Primary Postpartum Haemorrhage</u> (as part of management pathway) IM: 250microg. If uterus still atonic after 15 minutes repeat dose, and arrange a Cat 1 transfer to theatre. In theatre, doses can be repeated every 15 minutes to a maximum total dose of 2mg (8 ampoules)
Administration	<u>IM Injection ONLY</u>
Pregnancy	1st Trimester: Contraindicated 2nd Trimester: Contraindicated 3rd Trimester: Contraindicated
Breastfeeding	Commonly used in obstetrics without complications in breastfeeding mothers
Monitoring	Do not use in women with cardiac or pulmonary disease, hepatic or renal insufficiency, or allergy to prostaglandins. Use with caution in women with asthma
Clinical guidelines and protocols	KEMH Clinical Guideline: O&G: Postpartum complications KEMH Clinical Guideline: O&G: Caesarean Birth
References	The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Management of Postpartum Haemorrhage. [Internet] 2017 [cited 2018 Jun 12] Hale TW. Carboprost. In: Medications and Mothers' Milk [Internet]. New York: Springer Publishing Company; 2017 [cited 2018 Jun 28]. Available from: http://www.medsmilk.com Sundhedsstyrelsen. Summary of Product Characteristics for Prostinfer,

	solution for injection. Danish Health and Medicines Authority (Denmark); 2014 [cited 2018 Jun 28]
--	---

Keywords:	Carboprost, primary postpartum haemorrhage, PPH, dinoprost, prostaglandin F2 α , prostaglandin F2-alpha		
Publishing:	<input checked="" type="checkbox"/> Intranet	<input checked="" type="checkbox"/> Internet	
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	June 2015	Version:	3.3
Last reviewed:	Mar 2017, Jun 2018, Mar 2020, Feb 2022	Next review date:	June 2021
Endorsed by:	Medicines and Therapeutics Committee	Date:	Jan 2019
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from the WNHS website.</p> <p>For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au</p>			

© Department of Health Western Australia 2018